Scarica l'app Stockscreener
7.13
4.55%
-0.34
Pre-mercato:
7.18
0.05
+0.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsWeekly Risk Summary & Fast Gain Stock Trading Tips - Улправда
Q4 Earnings Estimate for BCRX Issued By HC Wainwright - MarketBeat
HC Wainwright Has Bullish Estimate for BCRX FY2025 Earnings - MarketBeat
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? - Yahoo Finance
FDA extends Orladeyo approval to children as young as 2 - Angioedema News
BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval By Investing.com - Investing.com Nigeria
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval - Investing.com UK
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - sharewise.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
The Technical Signals Behind (BCRX) That Institutions Follow - news.stocktradersdaily.com
Aug Highlights: Is BioCryst Pharmaceuticals Inc stock oversold or undervaluedJuly 2025 Sentiment & Risk Controlled Swing Alerts - moha.gov.vn
FDA approves BioCryst’s oral pellet version of rare disease drug for children - WKZO
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst wins FDA approval for Orladeyo oral pellets - MSN
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharma stock maintains Buy rating at TD Cowen on Orladeyo pediatric approval - Investing.com
BioCryst’s Orladeyo wins expanded FDA approval - The Pharma Letter
BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug - Benzinga
BioCryst Announces Board Chair Transition Plan - TipRanks
FDA approves berotralstat for patients aged 2 to 11 years with hereditary angioedema - Contemporary Pediatrics
Sector Update: Health Care Stocks Edge Higher Premarket Friday - marketscreener.com
Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? - Stocktwits
BioCryst stock rises after FDA approves ORLADEYO oral pellets for children - Investing.com Canada
FDA Approves BioCryst's (BCRX) Oral Pellet Formulation of Orlade - GuruFocus
FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children - Investing.com
BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha
FDA Gives Green Light to BioCryst's (BCRX) ORLADEYO for Pediatri - GuruFocus
FDA approves BioCryst’s ORLADEYO oral pellets for HAE in children By Investing.com - Investing.com Australia
BioCryst Pharmaceuticals Announces FDA Approval of ORLADEYO Oral Pellets as First Targeted Prophylactic Therapy for Pediatric Patients with HAE Aged 2 and Older - Quiver Quantitative
FDA expands approval of BioCryst's rare disease drug for use in young children - marketscreener.com
BioCryst (Nasdaq: BCRX) gains FDA nod for 1st oral HAE prophylaxis, ages 2- - Stock Titan
Nebula Research & Development LLC Invests $2.57 Million in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com India
Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in the Therapeutics | DelveInsight - The Globe and Mail
Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Trading Action: Can BioCryst Pharmaceuticals Inc stock hit analyst price targetsJuly 2025 Catalysts & Trade Opportunity Analysis Reports - moha.gov.vn
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Jump Financial LLC - MarketBeat
JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Would You Still Hold BioCryst Pharmaceuticals Stock If It Fell 30%? - Trefis
BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership - MarketBeat
BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why BioCryst Pharmaceuticals Inc. stock is seen as undervalued2025 Short Interest & Verified Short-Term Trading Plans - Newser
Is BioCryst Pharmaceuticals Inc. stock a good choice for value investorsVolume Spike & Reliable Price Action Trade Plans - Newser
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $646,128.40 in Stock - MarketBeat
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock - MarketBeat
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
BioCryst Pharma (BCRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Panagora Asset Management Inc. Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BioCryst (BCRX) Awards Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How BioCryst Pharmaceuticals Inc. stock reacts to global recession fearsPortfolio Profit Report & Free Community Consensus Stock Picks - Newser
BioCryst receives antitrust clearance for Astria acquisition By Investing.com - Investing.com Canada
0.66%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):